Yuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, Naoko Ishida, Kieko Yamazaki, Rie Horii, Yoshiya Horimoto, Norikazu Masuda, Hiroyuki Yasojima, Touko Inao, et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncology letters. 2019. 17. 2. 2177-2186
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. BREAST CANCER. 2017. 24. 3. 473-482
Hiroko Yamashita, Akiko Ogiya, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Tomofumi Osako, Masato Takahashi, Yumi Endo, Mitsuchika Hosoda, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. BREAST CANCER. 2016. 23. 6. 830-843
Naoko Ishida, Kazuhiro Araki, Takehiko Sakai, Kokoro Kobayashi, Takayuki Kobayashi, Ippei Fukada, Mitsuchika Hosoda, Mitsugu Yamamoto, Kazuomi Ichinokawa, Shunji Takahashi, et al. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience. BREAST CANCER. 2016. 23. 4. 617-623
Yuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, Naoko Ishida, Kieko Yamazaki, Rie Horii, Yoshiya Horimoto, Norikazu Masuda, Hiroyuki Yasojima, Touko Inao, et al. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. BREAST CANCER RESEARCH. 2016. 18